8 Recruiting Chronic Lymphocytic Leukemia Clinical Trials in Massachusetts
Explore active chronic lymphocytic leukemia research studies enrolling across Massachusetts. Verify eligibility and contact site coordinators.
📍 Find Near Me by DistanceBrowse by City
Recruiting Chronic Lymphocytic Leukemia Studies in Massachusetts
🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
📍 Beth Isreal Deaconess Medical Center — Boston, Massachusetts
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Safe Accelerated Venetoclax Escalation in CLL
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
📍 Research Site — Boston, Massachusetts
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
View Study & Checklist ➔ 🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research
Understanding Chronic Lymphocytic Leukemia
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔